CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
allogenic adipose stem cell injection +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02298023
NCT02298023Phase 2Completed

Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.

Seoul National University Hospital·interventional·Posted Nov 21, 2014·Updated Oct 19, 2021

In Brief

A Phase 2 clinical trial evaluating allogenic adipose stem cell injection, fibrin glue/normal saline injection, and 1 other intervention for Rotator Cuff Tear. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Main purpose of this study is to evaluate efficacy of allogenic adipose-derived mesenchymal stem cells in treatment of tendon injury. ALLO-ASC will be administrated to the patients with supraspinatus partial thickness tear by ultrasonographic guided injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 21, 2014
Enrollment StartSep 1, 2014
Primary CompletionJul 19, 2016
Study CompletionApr 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.6 years ago

Interventions

allogenic adipose stem cell injectionbiological

Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.

fibrin glue/normal saline injectionbiological

Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise

normal saline injectionbiological

Total 1cc of normal saline injection and range of motion exercise